<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuznar, Wayne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Sinn, Marianne</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">SOR as Adjuvant Therapy after Resection for Pancreatic Cancer Does Not Improve DFS</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">21-21</style></pages><abstract><style  face="normal" font="default" size="100%">Even after successful surgery intended as curative, up to 90% of patients with pancreatic cancer suffer a relapse. Adding sorafenib to gemcitabine as adjuvant therapy for patients after R1 resection for pancreatic cancer does not improve disease-free survival or overall survival compared with GEM alone. This article presents results from the phase 2b CONKO-006 study.</style></abstract><number><style face="normal" font="default" size="100%">36</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>